Human papillomavirus: Science and technologies for the elimination of cervical cancer

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 14, 2011, Pages 2189-2204

  Bosch, F Xavier ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

epidemiology; genital cancer; human papillomavirus; oncology

Indexed keywords

MESSENGER RNA; PROTEIN P16; VIRUS DNA; WART VIRUS VACCINE;

CANCER CONTROL; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT CANCER; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HISTOLOGY; HUMAN; MOUTH CANCER; ONCOGENE; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DNA PROBES, HPV; FEMALE; HUMANS; MALE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SECONDARY PREVENTION; TECHNOLOGY, PHARMACEUTICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 80052643782     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.596527     Document Type: Review

References (62)

1. International Agency for Research on Cancer (IARC).The 2007 IARC monograph on carcinogenesis [IARC 90]. 2007
2. de Sanjose S, QuinWG, Klaustermeier J, et al. HPV type distribution in invasive cervical cancer: the world prespective. Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop, November 3-10, 2007, Beijing, China
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009;10:321-2
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802
5. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85 (Pubitemid 38924707)
6. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Pubitemid 29406813)
8. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73
9. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32 (Pubitemid 46986496)
10. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87
11. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191-9 (Pubitemid 41603267)
12. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57:388-93 (Pubitemid 38446257)
13. Gravitt PE, Coutlee F, Iftner T, et al. New technologies in cervical cancer screening. Vaccine 2008;26(Suppl 10):K42-52
14. Quint WG, Pagliusi SR, Lelie N, et al. Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006;44:571-9 (Pubitemid 43222253)
15. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16
16. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27 (Pubitemid 36159887)
17. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15 (Pubitemid 43338210)
18. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):S300-10
19. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl 10):K29-41
20. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9 (Pubitemid 41417924)
21. Carozzi FM, Tornesello ML, Burroni E, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010;19:2389-400
22. Aylward RB, Hull HF, Cochi SL, et al. Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ 2000;78:285-97 (Pubitemid 30208319)
23. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-56 (Pubitemid 38942814)
24. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15-21
25. Bosch FX, de Sanjose S, Castellsague X. Evaluating the potential benefits of universal worldwide human papillomavirus vaccination. Therapy 2008;5:305-12 (Pubitemid 351781148)
26. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502
27. ISD (Information and Statistics Division), ISD Scotland (part of NHS National Services Scotland).Offical source for national statistics on health in Scotland. Available from: isd/5921 html [Last accessed September 2010]
28. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep 2007;56(RR-2):1-24
29. European Center for Disease Prevention and Control (ECDC).Guidance for the introduction of HPV vaccines European countries. Available from: . europa.eu/pdf/HPV-report pdf September 2008; [Last accessed September 2008]
30. World Health Organization. Global Advisory Committee on Vaccine Safety, 17 - 18 December 2008. Wkly Epidemiol Rec 2009;84:37-40 Available from: http:// www.who.int/vaccine-safety/en/
31. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl 10):K53-61
32. Centers for Disease Control and Prevention. Reports of health concerns following HPV vaccination. Available from: vaers/gardasil.htm [Last accessed May 2009]
33. Arbyn M, Sasieni P, Meijer CJ, et al. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl 3):S378-89
34. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101 (Pubitemid 44116919)
35. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-74 (Pubitemid 43983300)
36. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572-580
37. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94
38. Ronco G, Brezzi S, Carozzi F, et al. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol 2007;107(Suppl 1):S230-2 (Pubitemid 47483863)
39. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57
40. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97 (Pubitemid 47598401)
41. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72 (Pubitemid 350137476)
42. Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45(Suppl 1):S55-61
43. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011;129(3):691-701
44. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV Assay. J Clin Virol 2009;45(Suppl 1):S39-47
45. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17:3033-42
46. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(Suppl 3):S3171-7
47. Andrus JK, Sherris J, Fitzsimmons JW, et al. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008;26(Suppl 10):K87-92
48. Sankaranarayanan R, Bhatla N, Gravitt PE, et al. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008;26(Suppl 12):M43-52
49. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36
50. Brabin L, Kitchener HC, Stern PL. Implementation of prophylactic HPV vaccination: progress and future challenges. Expert Rev Obstet Gynecol 2010;5:591-603
51. Bulkmans NW, Bulk S, Ottevanger MS, et al. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. J Clin Pathol 2006;59:1218-20 (Pubitemid 44787150)
52. McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 2006;82:169-74
53. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26(Suppl 10):K76-86
54. Goldie SJ, Diaz M, Constenla D, et al. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008;26(Suppl 11):L59-72
55. Cervical Cancer Action. A Global Coalition to STOP Cervical Cancer. Progress in Cervical Cancer Prevention: the CCA Report Card; 2011. p. 1-28
56. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008;26(Suppl 10):K62-7
57. Jagu S, Karanam B, Gambhira R, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009;101:782-92
58. Bosch FX. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time. J Natl Cancer Inst 2009;101:771-3
59. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet 2005;89(Suppl 2):S30-7
60. Sankaranarayanan R, Gaffikin L, Jacob M, et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005;89(Suppl 2):S4-12 (Pubitemid 40488754)
61. Kane MA, Sherris J, Coursaget P, et al. HPV vaccine use in the developing world. Vaccine 2006;24 (Suppl 3):S3132-9
62. World Health Organization. Meeting of the immunization strategic advisory group of experts. Wkly Epidemiol Rec 2009;84:1-16